355.0500 5.20 (1.49%)
NSE May 05, 2025 15:57 PM
Volume: 268.8K
 

355.05
1.49%

Aarti Drugs

Centrum Broking
Valuation and key risks: We see strong scope for re-rating and ADL using our conservative five-year AOCF/EV yield method to arrive at a TP of Rs940, implying an upside of 25% over CMP. We expect the company to report RoE of 23% and RoCE of 15% for FY20. ADL outscores many of its peers due to its efficacious presence in the domestic and emerging markets and its integration across the value chain. Key risks to our call include slowdown in the domestic market and regulatory risks for its...
Aarti Drugs Ltd. is trading below its 50 day SMA of 356.2
More from Aarti Drugs Ltd.
Recommended